Shunji Morita

Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma

Shunji Morita, Masahiko Yano, Toshimasa Tsujinaka et al. · International Journal of Cancer · 1999 · 124 citations · Full text

CYP1A1 CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus

Shunji Morita, Masahiko Yano, Hitoshi Shiozaki et al. · International Journal of Cancer · 1997 · 81 citations · Full text

Cyp1a1 Cyp2e1, Squamous-cell Carcinoma, Epidemiology +14

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial

Junichi Nishimura, Taroh Satoh, Mutsumi Fukunaga et al. · European Journal of Cancer · 2015 · 70 citations

Combination Antiemetic Therapy, Gastrointestinal Oncology, Medicine +6

Association between genetic polymorphisms of glutathioneS-transferase P1 andN-acetyltransferase 2 and susceptibility to squamous-cell carcinoma of the esophagus

Shunji Morita, Masahiko Yano, Toshimasa Tsujinaka et al. · International Journal of Cancer · 1998 · 61 citations

Does Serum CA19-9 Play a Practical Role in the Management of Patients With Colorectal Cancer?

Shunji Morita, Takashi Nomura, Yukio Fukushima et al. · Diseases of the Colon & Rectum · 2004 · 57 citations